What do systematic reviews say?

135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel

135 mg/m2 paclitaxel showed no clear difference in progression‐free survival compared with 175 mg/m2 paclitaxel (low certainty).

• Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
  HR 1.09 [0.94, 1.28]
  1 study · 407 participants
  Low

135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel

135 mg/m2 paclitaxel showed no clear difference in neurotoxicity compared with 175 mg/m2 paclitaxel (low certainty).

• Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
  RR 0.19 [0.01, 3.99]
  1 study · 391 participants
  Low

135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel

The review found no eligible studies for this question.

• Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel

The review found no eligible studies for this question.

• Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Weekly paclitaxel vs three‐weekly paclitaxel

It is very uncertain whether weekly paclitaxel changes response rate ‐ platinum‐sensitive compared with three‐weekly paclitaxel (very low certainty).

• Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
  RR 1.13 [0.77, 1.65]
  2 studies · 100 participants
  Very low

Weekly paclitaxel vs three‐weekly paclitaxel

It is very uncertain whether weekly paclitaxel changes response rate ‐ platinum‐resistant compared with three‐weekly paclitaxel (very low certainty).

• Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
  RR 1.01 [0.55, 2.12]
  2 studies · 163 participants
  Very low

Weekly paclitaxel vs three‐weekly paclitaxel

The review found no eligible studies for this question.

• Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Weekly paclitaxel vs three‐weekly paclitaxel

It is very uncertain whether weekly paclitaxel changes progression‐free survival compared with three‐weekly paclitaxel (very low certainty).

• Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
  HR 0.83 [0.46, 1.52]
  2 studies · 263 participants
  Very low

Weekly paclitaxel vs three‐weekly paclitaxel

It is very uncertain whether weekly paclitaxel changes neurotoxicity compared with three‐weekly paclitaxel (very low certainty).

• Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
  RR 0.53 [0.19, 1.48]
  2 studies · 260 participants
  Very low

Weekly paclitaxel vs three‐weekly paclitaxel

Weekly paclitaxel may leads to lower neutropenia compared with three‐weekly paclitaxel (low certainty).

• Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
  RR 0.51 [0.27, 0.95]
  2 studies · 260 participants
  Low

Weekly paclitaxel vs three‐weekly paclitaxel

Weekly paclitaxel may leads to lower alopecia compared with three‐weekly paclitaxel (low certainty).

• Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
  RR 0.58 [0.46, 0.73]
  1 study · 205 participants
  Low

Hysterectomy (radical) with neoadjuvant chemotherapy vs chemoradiotherapy alone

Hysterectomy (radical) with neoadjuvant chemotherapy showed no clear difference in overall survival Median compared with chemoradiotherapy alone (moderate certainty).

• Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes only
  HR 0.94 [0.76, 1.16]
  2 studies · 1253 participants
  Moderate

Hysterectomy (simple or radical) with radiotherapy vs Radiotherapy alone

Hysterectomy (simple or radical) with radiotherapy showed no clear difference in progression‐free survival Median compared with radiotherapy alone (low certainty).

• Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes only
  HR 0.77 [0.54, 1.1]
  1 study · 256 participants
  Low

Hysterectomy (simple or radical) with radiotherapy vs Radiotherapy alone

• Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 118 participants
  Very low

Hysterectomy (simple or radical) with radiotherapy vs Radiotherapy alone

The review found no eligible studies for this question.

• Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Hysterectomy (simple or radical) with radiotherapy vs Radiotherapy alone

Hysterectomy (simple or radical) with radiotherapy may leads to higher severe/serious adverse events compared with radiotherapy alone (low certainty).

• Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes only
  OR 4
  2 studies · 374 participants
  Low

Hysterectomy (simple or radical) with chemoradiotherapy vs chemoradiotherapy alone

It is very uncertain whether hysterectomy (simple or radical) with chemoradiotherapy changes overall survival Median compared with chemoradiotherapy alone (very low certainty).

• Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 102 participants
  Very low

Hysterectomy (simple or radical) with chemoradiotherapy vs chemoradiotherapy alone

It is very uncertain whether hysterectomy (simple or radical) with chemoradiotherapy changes progression or event‐free survival Median compared with chemoradiotherapy alone (very low certainty).

• Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 163 participants
  Very low

Hysterectomy (simple or radical) with chemoradiotherapy vs chemoradiotherapy alone

The review found no eligible studies for this question.

• Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Hysterectomy (simple or radical) with chemoradiotherapy vs chemoradiotherapy alone

The review found no eligible studies for this question.

• Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found